- In February 2024, Pfizer Inc. and Genmab A/S announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for tisotumab vedotin. This antibody-drug conjugate (ADC) is being reviewed for the treatment of recurrent or metastatic pelvic cancer, offering a potential new therapeutic option for patients with limited treatment options
- In January 2024, Merck & Co., Inc. received U.S. FDA approval for Keytruda, a PD-1 inhibitor, for patients with stage 3 to 4a cancer. The approval includes the combination of Keytruda with chemoradiotherapy, marking a significant step forward in the treatment of advanced cancers by enhancing immune response and improving patient outcomes
- In December 2023, Pfizer Inc. completed its acquisition of Seagen Inc., a global biotechnology company. Seagen developed TIVDAK (tisotumab vedotin), a promising drug for the treatment of cancer. This acquisition strengthens Pfizer’s oncology portfolio and aims to accelerate the development of innovative cancer treatments, expanding treatment options for patients with cervical and pelvic cancers
- In June 2023, Nykode Therapeutics entered into a collaboration with F. Hoffmann-La Roche Ltd to conduct a clinical trial for advanced pelvic cancer. The trial investigates Nykode’s lead candidate, VB10.16, in combination with Roche's immunotherapy drug Tecentriq (atezolizumab). This partnership seeks to explore new therapeutic strategies for treating advanced pelvic cancer and enhancing patient survival rates
Frequently Asked Questions
The market is segmented based on Segmentation, By Origin Type (Kidney Cancer, Uterus Cancer, and Cervical Cancer), Therapy Type (Chemotherapy, Radiation Therapy, Targeted Therapy), Treatment Type (Medication, and Surgery), Mechanism of Action Type (Vascular Endothelial Growth Factor Inhibitor, DNA Synthesis Inhibitor, Topoisomerase Inhibitor, Programmed Death Receptor-1 (PD-1)-Blocking Antibody, Nucleoside Metabolic Inhibitor and Others), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics, and Others)– Industry Trends and Forecast to 2032
.
The Global Pelvic Cancer Drug Market size was valued at USD 1.06 USD Billion in 2024.
The Global Pelvic Cancer Drug Market is projected to grow at a CAGR of 14% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
